Sponsors (56)
Introduced November 20, 2025 by Frank Pallone · Last progress November 20, 2025
The bill would make prescription drugs, especially insulin, more affordable for many Americans through negotiation, caps, and rebate changes, but those gains are balanced by risks of manufacturer market responses, uneven plan opt-outs, reduced federal benefit protections for employer plans, and new compliance costs that could shift costs or limit access for some people.
Medicare beneficiaries and millions of patients with chronic conditions would likely pay less for many high-cost prescription drugs because the bill expands federal price negotiation, anchors prices to an average international market price, and adjusts rebate/accounting rules to better reflect commercial use.
People with diabetes would face much lower insulin cost-sharing, capped at $35 per 30-day supply or 25% of the negotiated price starting in 2027.
Enrollees would face a new annual out-of-pocket prescription drug cap (self-only $2,000 in 2027, then indexed), limiting catastrophic drug spending for many households.
Many consumers (including Medicare and privately insured patients) could still face higher costs if manufacturers, insurers, or plans shift prices or cost-sharing strategies in response to the new rules, or if indexing rules allow caps to grow with rapidly rising premiums.
Manufacturers may reduce U.S. product availability or delay launches (particularly for high-cost drugs) in response to negotiated prices or international price anchoring, which could limit treatment options for patients.
Some group health plans and issuers can opt out of substituting cost-sharing to the negotiated price, leaving those enrollees without the lower cost-sharing and creating uneven benefits across workers and markets.
Based on analysis of 4 sections of legislative text.
Expands federal drug price negotiation, extends negotiated maximum prices into many commercial plans by default (opt-out), revises rebate unit counts, and imposes new benefit and cost-sharing limits starting in 2027.
Expands the federal drug price negotiation program and makes negotiated maximum fair prices apply beyond Medicare to many commercial group and individual health plans by default unless plans affirmatively opt out, while requiring public disclosure of opt-outs. Changes how prescription drug use is counted for inflation rebates, requires plans to cap patient cost-sharing at negotiated prices, and adds new limits and benefit rules for individual and small-group market plans beginning in 2027; it also requires the Secretary to consider an average international market price for negotiations starting with certain negotiations on or after January 1, 2028.